News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

M²™ Multiplexed Microwell Diagnostic System From Dynex Technologies Chosen For University of California, Los Angeles (UCLA)/Gates Foundation Health Study In The Congo



1/8/2014 9:14:45 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CHANTILLY, Va.--(BUSINESS WIRE)--Dynex Technologies announced today it has conducted a successful field trial of its patented M²™ Multiplexed Microwell system to test for five different diseases with a single process as part of a serosurvey program in the Democratic Republic of the Congo (DRC). Dynex's MMRVT panel tested each patient for measles, mumps, rubella, varicella and tetanus in the program under the direction of Dr. Anne Rimoin, Associate Professor of Epidemiology at UCLA. These diseases present a significant danger of child mortality and congenital deformation of unborn children. The survey is designed to develop a nationwide immunity profile, which in turn will be used to design immunization programs within the DRC. In this work 40,000 respondents will be surveyed with 8,000 children being tested for MMRVT immunity via dried blood spot sample collection. The project is being funded by The Bill and Melinda Gates Foundation in partnership with UCLA and coordinated by the Kinshasa School of Public Health.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES